Montgomery County’s Bethesda Hyatt will be the venue for the CONNECTpreneur XVIII Forum on April 28. The event, which will be held 7:00 to 11:00 am, features a “fireside chat” with serial entrepreneur and CEO Mark Walsh.

With more than 250 CXO's and investors, along with a strong lineup of speakers and presenters, the Big Idea CONNECTpreneur XVIII Forum is shaping up to be a record-setting event.

Virginia Bio, the premier statewide non-profit association representing life science industry in the Commonwealth of Virginia, elected Dr. Reg Seeto, Vice President, Head of Partnering and Strategy at MedImmune, the biologics research and development arm of AstraZeneca, as a new member of their Board of Directors for a term of three years.

Economic Alliance of Greater Baltimore CEO Thomas Sadowski has taken a high-ranking economic development position with the state's public university system.

Sadowski, who has headed the business advocacy group known as the EAGB since 2008, is becoming the vice chancellor for economic development at the University System of Maryland. He'll start May 2 at the public education system, which is made up of a dozen institutions with 163,000 students.

Whether you are talking to peers, competitors or investors, you as an active entrepreneur will be judged on your familiarity with today’s startup and funding jargon. I’m not recommending that you saturate your discussions with lingo, but responding with a blank stare once-too-often won’t convince anyone that you can build the next world-changing business or outpace the market.

Blueprint Medicines is collaborating with Roche on the discovery, development and commercialisation of up to five targeted cancer immunotherapies, in a deal potentially worth more than $1 billion.

Johns Hopkins University graduate programs in nursing, education, medicine, and biomedical engineering remain among the best in the nation, according to the newest U.S. News & World Report rankings of "Best Graduate Schools."

The list, released on Wednesday, moves the university's School of Nursing master's degree program up from a tie for second place last year to the No. 1 spot this year.

Baltimore health IT startup Tissue Analytics has raised $1.9 million in debt to scale up its wound analysis business.

The funding comes from unnamed investors.

Every year TEDCO makes dozens of investments in the State’s most promising tech startups – this volume of deal flow makes TEDCO the “go to” seed stage funding source for Maryland entrepreneurs.

You may have heard about TEDCO’s TCF (Technology Commercialization Fund) and CIF (Cybersecurity Investment Fund) Programs and found yourself wondering “What are they?”, “What is TEDCO looking for?”, and “How can I maximize my chance of getting funded? – well…now help is on the way!!

Join us for an “entrepreneur only” workshop to learn how you can prepare a powerful application for these two TEDCO flagship funding programs. The first part of the workshop will cover the TCF/CIF process, application requirements and the key points every reviewer is looking for in an application. In the second half, entrepreneurs will have the chance to discuss their specific situations & questions with experienced TEDCO review committee members.

Every year in March, Women In Bio celebrates Women’s History Month (WHM) with events highlighting the most pressing issues for women in the biosciences/technology field. This year’s theme is “Expanding the 50-50 Challenge,” and our WIB-DC/Baltimore chapter WHM event will identify opportunities, barriers, and challenges for women who are becoming investors in their own right, as well as challenges for women entrepreneurs to access investment. On a broader note, our panel will discuss how women can identify and tackle with gender disparities in the professional environment through “investing” in their own and their female colleague’s professional goals.

For the last few years, the spotlight in start-up investing has largely shone on those who poured money into a company when it was already well along on a growth path. It turns out that spotlight may have been misdirected.

As venture capitalists focus more on bigger deals, a growing demand is developing for business accelerators and incubators to fund startups, Dreamit Ventures LLC CEO Avi Savar said Saturday at South By Southwest.

Who has the hot hand in venture capital?

To identify today’s top venture investors, CB Insights, a research firm that tracks the venture capital industry, created a data-driven list. The firm based its report on factors like connectedness, since people with access to the best information hear about hot companies first, and exits, meaning the returns generated when a start-up is sold or goes public. For exits, the firm considered the valuation and when the investor first put money into the company.

Health Wildcatters got recognized for the first time in an annual report ranking seed accelerators. It scored a Silver ranking while Healthbox attained a Gold in the Seed Accelerator Rankings Project.

Hubert Zajicek is the head of the Dallas-based Wildcatters accelerator, which has been around since 2012. It has 32 portfolio companies and is currently looking for applicants for its Fall class later this year.

Maryland-based biotechnology firm MaxCyte Inc Thursday said it plans to list on London's AIM market later this month.

The company expects to be admitted to AIM March 29, and plans to raise GBP10 million on admission. It expects to have a GBP30.4 million market capitalisation.

South Korean venture capital companies turn their eyes to promising biotech firms overseas, looking for a vehicle to accelerate their investment goals.

KTB Network recently joined hands with three Chinese venture capital companies to invest a total of 36 billion won ($30.1 million) in the country’s biopharma company CARsgen Therapeutics. The biotech company is highly praised for its immune cell therapy platform. It is working on a new method to treat patients with glioblastoma and hepatocellular carcinoma with a goal to conduct a clinical trial next year.

Becton Dickinson’s (NYSE:BDX) decision to spin off its respiratory devices into a joint venture with Apax Partners will allow it to offload an underperforming segment and concentrate on its core business of diagnostics. And the agreement also highlights the growing involvement of private equity in the medtech industry.

J. Craig Venter, Ph.D., is regarded as one of the leading scientists of the 21st century for his numerous contributions to genomic research. In addition to his past key positions, he is founder, current chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization dedicated to human, microbial, plant, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics.

Pittsburgh-area entrepreneurs will soon have another funding option for growing early phase startup companies.

Pharmaceutical giant GlaxoSmithKline has thrown its support behind the creation of a $100 million venture capital fund, which will help meet a need for early stage business startup capital in the Pittsburgh area. Philadelphia-based SG3 Ventures anticipates awarding its first round of funding in about a year, according to Brian McVeigh, vice president of worldwide business development transactions and investment management at GSK.

MedImmune has secured orphan drug designation from the the US Food and Drug Administration (FDA) for its MEDI-551 neuromyelitis optica drug.

MEDI-551 is an anti-CD19 monoclonal antibody indicated to treat neuromyelitis optica and neuromyelitis optica spectrum disorders.

Inner Harbor is the latest site of a new Baltimore incubator.

With Harbor Launch, the Institute of Marine and Environmental Technology (IMET) has designated areas of office and lab space specifically for biotech and environmental startups at Columbus Center (the big building with the sails on it near Pier Five).

Congratulations to Montgomery County Innovation Network Director John Korpela for receiving a service award from the Maryland Business Incubator Association on March 4 at the Germantown Innovation Center during its annual meeting. The award was presented by MBIA President Robert Snyder and recognizes John for his 12 years of service, leadership, and mentorship.

The Intramural Research Program of the National Institutes of Health (NIH) is seeking an outstanding individual to serve as Director of the Office of Technology Transfer (OTT), Office of Intramural Research, Office of the Director. The OTT provides support to the technology transfer functions of the NIH Institutes and Centers (ICs) that manage the patenting and licensing of inventions made by scientists in the NIH intramural research program. The OTT is responsible for negotiating amendments to these licenses and for patent license enforcement activities. OTT also manages the administration of royalties ($138M in FY2014), which are distributed to inventors, ICs where the inventions were made, and to co-inventors under Inter-Institutional Agreements. OTT manages multiple IT systems which track the NIH invention lifecycle including data and documentation workflows. It manages the docketing of all patent correspondence from contract law firms, receiving and processing new invention disclosures, marketing of NIH licensing opportunities, central reporting of NIH-wide technology transfer data, and necessary training in the use of the centralized database. The incumbent has overall responsibility for strategic and tactical operational planning, and financial management for the OTT. The Director of OTT reports to the Deputy Director for Intramural Research, NIH.

Angel investment funding in healthcare increased in 2015, compared with the previous years, according to a new report from the Angel Resource Institute and PitchBook. The 2015 Annual Halo Report found that healthcare deals accounted for 23 percent of angel investment.

When Inova Health System announced it would create a $100 million venture fund— unveiled as part of a splashy White House event last month highlighting precision medicine investments— it was just the kind revelation Inova has gotten so good at making in the last year.

Heart disease, cancer, diabetes, obesity, arthritis—chronic conditions such as these account for 84% of health care spending. Yet many are preventable. An estimated 40% of all premature deaths can be attributed to lifestyle, such as smoking and inactivity. How can the health care system shift focus (and dollars) from acute to preventative care?

Almost every day, we see announcements about yet another “connected” product that is hailed as creating a “smarter” home environment. These types of products promise an easier, more convenient way of living, but they aren’t always connected to our lives—or all that smart. 

AstraZeneca PLC on Wednesday said its MedImmune research and development arm has secured orphan drug designation for its MEDI-551 drug from the US Food & Drug Administration.

The drugmaker said MEDI-551 is used to treat patients with neuromyelitis optica, an autoimmune disease of the central nervous system by which the body's immune system attacks healthy cells, most commonly in the optic nerves and spinal cord.

It was one major issue U.S. Commerce Secretary Penny Pritzker and National Urban League President Marc Morial discussed with entrepreneurs Monday.

AstraZeneca announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational human monoclonal antibody (mAb), MEDI8852, for the treatment of patients hospitalised with Type A strain influenza. The FDA’s Fast Track programme is designed to expedite the development and review of drugs to treat serious conditions and fill an unmet medical need.

It looks like Healthbox is raising a new fund, according to a Form D filing with the U.S. Securities and Exchange Commission. The accelerator is keeping schtum about the Healthbox Opportunity Fund I and declined a request for comment.

Still, its website shows that it is poised to bring its Healthbox Studio accelerators to Orlando, as part of a partnership with Guidewell Innovation Center, and Los Angeles later this year. Healthbox and Guidewell had previous accelerator classes in Miami, Tampa Bay and Jacksonville. Los Angeles is home to a few accelerators, including one between Techstars and Cedars-Sinai.

A University of Maryland startup is among the finalists in Under Armour CEO Kevin Plank's Cupid's Cup, a competition offering a $100,000 prize of the winner.

Companies founded on technology licensed from Johns Hopkins University have raised $1 billion since 2010. And 90 percent of those companies are no longer in Maryland.

Christy Wyskiel, who leads Johns Hopkins Technology Ventures, the university’s commercialization arm, hopes to reverse that trend with a new partnership with Village Capital and the Abell Foundation.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for its BD Totalys MultiProcessor and BD Totalys SlidePrep instruments.

Innovation takes time – and money, and people and resources. That’s why it’s common for a company to focus on core business activities and not build an innovation lab – a specific building or department dedicated to working on prototypes and fleshing out ideas. 

Remarkable progress has been made over the last century in enhancing public health, driven largely by advances in science, medicine and our understanding of how disease manifests in the human body. As a result, the average life expectancy doubled during the 20th century.